We Give Shareholders a Voice
Levi & Korsinsky is investigating the Board of Directors of Derma Sciences, Inc. (“Derma Sciences”) (NASDAQ: DSCI) in connection with the sale of the Company to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A Convertible Preferred Stock will receive $32 per share, and holders of Series B Convertible Preferred Stock will receive $48 per share.
The investigation concerns whether the Board of Derma Sciences breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Integra LifeSciences Holdings Corporation is underpaying for Derma Sciences shares.
To receive more information, please fill out the form.